Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.62 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.62 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.47 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26609498 | 0.93 | IKZF2 (0.62) | IKZF2IKZF1CRBNCSNK1A1IKZF3 | |
| SCHEMBL26610358 | 0.92 | IKZF2 (0.59) | IKZF2IKZF1CRBNCSNK1A1IKZF3 | |
| SCHEMBL26608889 | 0.92 | IKZF2 (0.73) | IKZF2IKZF1CRBNCSNK1A1IKZF3 | |
| SCHEMBL26609180 | 0.91 | IKZF2 (0.60) | IKZF2IKZF1CRBNCSNK1A1IKZF3 | |
| SCHEMBL26608715 | 0.91 | CRBN (0.58) | IKZF2IKZF1CRBNCSNK1A1IKZF3 | |
| SCHEMBL26609416 | 0.91 | IKZF2 (0.64) | IKZF2IKZF1CRBNCSNK1A1 | |
| SCHEMBL26609624 | 0.90 | IKZF2 (0.61) | IKZF2IKZF1CRBNCSNK1A1MAP1LC3B | |
| SCHEMBL26608524 | 0.89 | IKZF2 (0.58) | IKZF2IKZF1CRBNCSNK1A1IKZF3 | |
| SCHEMBL23092333 | 0.89 | IKZF2 (0.65) | IKZF2IKZF1CRBNCSNK1A1 | |
| SCHEMBL26609316 | 0.89 | IKZF2 (0.63) | IKZF2IKZF1CRBNCSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CSNK1A1, CSNK1D, CSNK1G1 | IKZF2 2228/4885IKZF1 2053/4885CRBN 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.